Tardive Dyskinesia
A condition affecting the nervous system, often caused by long-term use of some psychiatric drugs.
Tardive dyskinesia is caused by long-term use of neuroleptic drugs, which are used to treat psychiatric conditions.
Tardive dyskinesia causes repetitive, involuntary movements, such as grimacing and eye blinking.
Stopping or tapering drugs that may be contributing to involuntary repetitive movements can help. In rare cases, botulinum toxin, deep brain stimulation, or medications can help.
Cluster Number:
Wiki Number: PW216
Diagnosis: Tardive Dyskinesia
US Patients: 30% of those taking antipsychotic medicines
World Patients:
Sex Ratio: M;F+
Age Onset: elderly
Brain Area:
Symptoms: involuntary, repetitive body movements: rapid-jerking or slow-writhing; grimacing, smacking lips, sticking out tongue, eye-blinking
Progression: walking is difficult or impossible due to excess leg movement
Causes: reactions to narcoleptic drugs; reactions to long-term-use of dopamine-receptor-blocking medications; antipsychotics
Medications: supersensitivity to dopamine becomes in the nigrostriatal pathway;discontinuing the narcoleptics helps; valbenazing, etc.
Therapies: No therapies listed; newer antipsychotic drugs cause less dyskinesia than the first generation of antipsychotic drugs did.
Youtube Video: Meet Jeff, Living with Tardive Dyskinesia
Amazon or Library Book:
Ultimate Medical Guide to Tardive Dyskinesia
Click the book to link or order from Amazon.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosisÂ
Clicking each title opens the
PubMed article’s summary-abstract.
- Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) databaseby Guangwei Qing on February 22, 2025
CONCLUSION: This research has yielded initial safety insights into the practical use of deutetrabenazine, validating established adverse reactions and uncovering further possible risks. These findings present essential safety considerations for physicians when prescribing deutetrabenazine for the clinical treatment.
- Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesiaby Chenghao Lu on February 21, 2025
CONCLUSIONS: In TD, disruptions in amino acid and lipid metabolism were predominantly observed. Amino acids and lipid metabolites may be involved in the development of TD. Additionally, a biomarker panel composed of amino acids and lipids can be used for the differential diagnosis of TD.
- From Assessment to Intervention: Evidence-Based Approaches in Tardive Dyskinesiaby Desiree Matthews on February 12, 2025
No abstract
- Sensori- and psychomotor abnormalities, psychopathological symptoms and functionality in schizophrenia-spectrum disorders: a network analytic approachby Stefan Fritze on February 12, 2025
Sensori- and psychomotor abnormalities are an inherent part of schizophrenia-spectrum disorders (SSD) pathophysiology and linked to psychopathological symptoms as well as cognitive and global functioning. However, how these different symptom clusters simultaneously interact with each other is still unclear. Here, we examined 192 SSD patients (37.75 ± 12.15 years, 73 females). First, we investigated the cross-sectional prevalence and overlap of individual sensori- and psychomotor abnormalities....